In a cell culture–based screen we used single concentrations of each of the ATR, ATM, and DNA-PK inhibitor drugs that caused approximately 20%–45% loss of viability in the ccRCC cells after 72 hours of treatment (Figure 6A). The gene discussed is ATR; the disease is nonpapillary renal cell carcinoma.